News Latest news from the fund and the industry

Octarine receives funding to develop biosynthetic platform for cannabinoid and psilocybin derivatives
Octarine Bio IVS (“Octarine” or the “Company”), a synthetic biology company developing functionally superior cannabinoid and psilocybin derivatives…
Read more